Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 4 Interventional Results available

Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

NCT04387773
View directory record Official record
Conditions
Parkinson Disease
Interventions
GOCOVRI
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 4 Interventional

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

NCT00160173
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Estrogel, Placebo
Drug · Other
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

NCT00227370
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Assessment of LBR-101 In Chronic Migraine

NCT02021773
View directory record Official record
Conditions
Chronic Migraine
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

NCT03842969
View directory record Official record
Conditions
Huntington Disease
Interventions
RO7234292 (RG6042)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT05581641
View directory record Official record
Conditions
Malaria
Interventions
BNT165b1, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 23, 2026, 6:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of CBD on 2 Mile Run Time Trial Performance

NCT06364254
View directory record Official record
Conditions
Healthy
Interventions
Cannabidiol Capsules
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Greeley, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 5461 in Healthy Volunteers

NCT02068105
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

NCT00000866
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1, TBC-3B Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6423 SAD/MAD Study in Healthy Volunteers

NCT01926366
View directory record Official record
Conditions
Healthy Volunteers.
Interventions
AZD6423, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

NCT01604824
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

NCT02451579
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Antihistamine Cetirizine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 23, 2026, 6:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962
View directory record Official record
Conditions
Focal Epilepsy
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 23, 2026, 6:57 AM EDT
Enrolling by invitation Phase 4 Interventional

Trial of Reducing Inpatient Antibiotic Durations in Children

NCT07322146
View directory record Official record
Conditions
Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions
Study Drug Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Days to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

NCT05976646
View directory record Official record
Conditions
Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions
Placebo, Auvelity
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

NCT05896527
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DC-806, Placebo
Drug · Other
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Fountain Valley, California • Santa Monica, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 6:57 AM EDT
Withdrawn Not applicable Interventional

Caffeine Versus Placebo for Spinal Headaches

NCT00809627
View directory record Official record
Conditions
Post Dural Puncture Headache
Interventions
Caffeine, saline
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes

NCT01034527
View directory record Official record
Conditions
ACL Injury
Interventions
Neuromuscular Training
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years · Female only
Enrollment
593 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

NCT01186861
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions
OSI-906, erlotinib, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Jacksonville, Florida • Port Saint Lucie, Florida • Albany, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

AZD6765 for Treatment Resistant Depression

NCT00491686
View directory record Official record
Conditions
Depression
Interventions
AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Glendale, California • Hartford, Connecticut • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2011 · Synced Oct 23, 2026, 6:57 AM EDT
Not listed Phase 2 Interventional

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

NCT01782170
View directory record Official record
Conditions
Gingivitis, Investigation of Biological Markers of Inflammation
Interventions
Iocide Oral Rinse, Placebo
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Results available

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

NCT04806373
View directory record Official record
Conditions
Pleural Effusion
Interventions
Cathflo Activase, Talc Slurry Pleurodesis
Drug
Lead sponsor
Memorial Healthcare System
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 23, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069
View directory record Official record
Conditions
Sarcoidosis
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 23, 2026, 6:57 AM EDT